

**BOEHRINGER INGELHEIM AND ABGENOMICS CORPORATION SIGN  
WORLDWIDE EXCLUSIVE COLLABORATION AND LICENSE  
AGREEMENT TO DEVELOP AND COMMERCIALIZE A THERAPEUTIC  
MONOCLONAL ANTIBODY**

*Ingelheim, Germany and Taipei, Taiwan, XX May 2005* - Boehringer Ingelheim International GmbH and AbGenomics Corporation announced today that they have signed an exclusive licensing agreement providing Boehringer Ingelheim with the worldwide exclusive rights to develop, manufacture and commercialize any products with AbGenomics Corporation's antibody 168. Based on data generated by AbGenomics Corporation, antibody 168 may potentially be developed to treat a broad range of immune-related diseases. The initial focus of the development will be on therapies for autoimmune diseases. Specific terms of the transaction were not disclosed but they are comparable to the average licensing deals for compound of a similar stage and market potential. Also, AbGenomics Corporation has an option to co-promote in selected Asian countries.

“Monoclonal antibodies are an increasingly important component of medical treatments. AbGenomics Corporation's antibody 168, with its novel mechanism of action, has the potential of introducing a new therapeutic paradigm for the treatment of autoimmune diseases. Our agreement with AbGenomics Corporation is the latest example of our corporate strategy to build long-term growth by focusing on biopharmaceuticals and on potential disease areas with unmet medical needs.” said Dr Andreas Barner Vice Chairman of the Board Corporate Division Pharma Research, Development and Medicine at Boehringer Ingelheim.)

“This licensing deal underlines our strategy of collaborating with international pharma partners who bring specialized skills and know-how to accelerate the development and marketing of our compounds. Boehringer Ingelheim, an outstanding company with world-class pharmaceutical business and a world leader in the manufacturing of biopharmaceuticals, is an ideal partner. We are enthusiastic about working with Boehringer Ingelheim and are also very optimistic that this agreement will bring our proprietary monoclonal antibody to patients around the world” commented Dr Rong-Hwa Lin, Chairman of the Board and Chief Executive Officer of AbGenomics Corporation.

### **About Boehringer Ingelheim**

The Boehringer Ingelheim group is one of the world's 20 leading pharmaceutical companies. Headquartered in Ingelheim, Germany, it operates globally with 144 affiliates in 45 countries and nearly 36,000 employees. Since it was founded in 1885, the family-owned company has been committed to researching, developing, manufacturing and marketing novel products of high therapeutic value for human and veterinary medicine.

In 2004, Boehringer Ingelheim posted net sales of 8.2 billion euro while spending nearly one fifth of net sales in its largest business segment Prescription Medicines on research and development.

For more information please visit [www.boehringer-ingelheim.com](http://www.boehringer-ingelheim.com)

### **About AbGenomics Corporation**

AbGenomics Corporation, headquartered in Taipei, Taiwan, is a biotechnology company focused on the discovery and development of breakthrough medicines to treat serious, life threatening and debilitating diseases, including cancer, inflammation, autoimmune, infectious and metabolic diseases. The Company's strategy is to commercialize its products both independently and in collaboration with major pharmaceutical partners which can enhance the development and marketing of Company's compounds.

For more information about AbGenomics Corporation, please visit its website at [www.abgenomics.com](http://www.abgenomics.com).

### **Forward looking statements**

This press release contains forward-looking statements. These statements are inherently subject to risks and uncertainties, which may cause results to differ materially from those set forth in the statements. The forward-looking statements include, among other things, statements regarding product development. There can be no assurance that such development efforts will succeed, that such products will receive required regulatory clearance or that, even if such regulatory clearance were received, such products would ultimately achieve commercial success. While the Companies make their best efforts to be accurate in making forward-looking statements, such statement cannot be guaranteed. The Companies undertake no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise.

**Contact:**

Ogilvy Public Relations Worldwide

Celeste Lu

Taiwan

Phone: +886-2-3725-1231

E-mail: [celestect.lu@ogilvy.com](mailto:celestect.lu@ogilvy.com)